FDA approves tafasitamab-cxix
On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab.
Related Articles
Another Option for Metastatic Prostate Cancer | Cancer Today
PSMA-targeted therapy, which delivers radiation directly to cancer cells, provides a new approach for those whose prostate cancer stops responding to other treatments.
AACR Team Science Award
This award acknowledges and catalyzes the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer…
FDA approves neoadjuvant and adjuvant pembrolizumab for resectable loc
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c
June 20: The Week in Cancer News | Cancer Today
Surgery to remove fallopian tubes can lower ovarian cancer risk, and NIH staff cuts lead to delays for patients.
AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
This award recognizes an individual in any subfield or sector of cancer research and cancer-related sciences who has contributed significantly to the education and training…
AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research
Overview for AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research
Registration
Register for the AACR Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.
Outbreak Investigation of Listeria monocytogenes: Chicken Fettuccine
Do not eat or serve recalled chicken fettuccine alfredo meals made by certain FreshRealm, Inc. facilities. FDA’s investigation is ongoing.
FDA Adds Warning About Serious Risk of Heat-Related Complications
The patch can increase body temperature and cause heat-related complications, resulting in hospitalization or even death in some cases
